Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 94.17M
March 31, 2026 92.40M
December 31, 2025 90.92M
September 30, 2025 89.46M
June 30, 2025 89.10M
March 31, 2025 88.79M
December 31, 2024 87.45M
September 30, 2024 77.91M
June 30, 2024 76.46M
March 31, 2024 76.11M
December 31, 2023 75.37M
September 30, 2023 75.11M
June 30, 2023 74.97M
March 31, 2023 74.59M
December 31, 2022 64.29M
September 30, 2022 64.15M
June 30, 2022 63.84M
March 31, 2022 63.51M
December 31, 2021 62.49M
September 30, 2021 61.02M
June 30, 2021 60.71M
March 31, 2021 60.44M
December 31, 2020 52.25M
September 30, 2020 51.02M
June 30, 2020 50.90M
Date Value
March 31, 2020 43.15M
December 31, 2019 43.09M
September 30, 2019 42.96M
June 30, 2019 42.90M
March 31, 2019 41.44M
December 31, 2018 41.39M
September 30, 2018 41.17M
June 30, 2018 40.37M
March 31, 2018 39.87M
December 31, 2017 39.37M
September 30, 2017 39.28M
June 30, 2017 38.29M
March 31, 2017 38.16M
December 31, 2016 37.91M
September 30, 2016 37.70M
June 30, 2016 36.73M
March 31, 2016 36.59M
December 31, 2015 36.47M
September 30, 2015 36.01M
June 30, 2015 35.07M
March 31, 2015 34.85M
December 31, 2014 26.05M
September 30, 2014 26.32M
June 30, 2014 26.30M
March 31, 2014 24.42M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
TG Therapeutics, Inc. 153.08M
BioMarin Pharmaceutical, Inc. 193.54M
Vertex Pharmaceuticals, Inc. 253.35M
Viridian Therapeutics, Inc. 113.24M
Krystal Biotech, Inc. 29.60M